BofA raised the firm’s price target on McKesson (MCK) to $970 from $950 and keeps a Buy rating on the shares following a “strong quarter” with revenue and EPS ahead of Street expectations. The firm is raising FY26 and FY27 EPS estimates primarily due to strong execution in the North American Pharmaceutical segment EBIT and Oncology & Multispecialty segment EBIT.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK: